Pharvaris Q3 2026 loss widens 28% to €47.4 million
PHVS•Pharvaris’ third-quarter 2026 loss widened 28% year over year to €47.4 million. Cash and cash equivalents stood at €283 million on September 30, while the FDA is reviewing deucrictibant IR with an April 23, 2027, decision deadline.
1. Quarterly results
Pharvaris’ third-quarter 2026 loss widened 28% year over year to €47.4 million. General and administrative expenses rose 81% to €17.7 million, and research and development spending increased 9% to €32.4 million. Cash and cash equivalents fell to €283 million at September 30, 2026.
2. Deucrictibant timeline
The FDA is reviewing deucrictibant IR for on-demand treatment of HAE attacks, with a decision deadline of April 23, 2027. Pharvaris said a U.S. application for deucrictibant XR to prevent bradykinin-mediated angioedema attacks remains on track for submission in the first half of 2027.
